

- D. C. (1975) *Proc. Natl. Acad. Sci. U.S.A.* 72, 1349-1353.  
 Ruegg, C., & Lerch, K. (1981) *Biochemistry* 20, 1256-1262.  
 Schoot Uiterkamp, A. J. M., & Mason, H. S. (1973) *Proc. Natl. Acad. Sci. U.S.A.* 70, 993-996.  
 Solomon, E. I. (1981) in *Copper Proteins* (Spiro, T. G., Ed.) Chapter 2, Wiley-Interscience, New York.  
 Stenkamp, R. E., Sieker, L. C., Jensen, L. H., & Sanders-Loehr, J. (1981) *Nature* 291, 263-264.  
 Strothkamp, K. G., Jolley, R. L., & Mason, H. S. (1976) *Biochem. Biophys. Res. Commun.* 70, 519-524.  
 Suzuki, S., & Nakahara, A. (1982) *Bull. Chem. Soc. Jpn.* 55, 212-217.  
 Valentine, J. S., Pantoliano, M. W., McDonnell, P. J., Burger, A. R., & Lippard, S. J. (1977) *Proc. Natl. Acad. Sci. U.S.A.* 76, 4245-4249.  
 Wilcox, D. E., Porras, A. G., Hwang, Y. T., Lerch, K., Winkler, M. E., & Solomon, E. I. (1985) *J. Am. Chem. Soc.* 107, 4015-4027.  
 Winkler, M. E., Lerch, K., & Solomon, E. I. (1981) *J. Am. Chem. Soc.* 103, 7001-7003.

## Substrate Specificities and Mechanism in the Enzymatic Processing of Vitamin A into 11-*cis*-Retinol<sup>†</sup>

Francisco J. Cañada, Wing C. Law, and Robert R. Rando\*

*Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115*

Toshihiro Yamamoto, Fadila Derguini, and Koji Nakanishi\*

*Department of Chemistry, Columbia University, New York, New York 10027*

*Received April 24, 1990; Revised Manuscript Received July 11, 1990*

**ABSTRACT:** The biosynthesis of 11-*cis*-retinol in the retinal pigment epithelium requires two consecutive enzymatic reactions. The first involves the esterification of *all-trans*-retinol by lecithin retinol acyltransferase (LRAT). The second reaction involves the direct conversion of an *all-trans*-retinyl ester into 11-*cis*-retinol by an isomerase-like enzyme. This latter reaction couples the free energy of hydrolysis of an ester to the thermodynamically uphill trans to cis conversion, thus providing the energy to drive the latter process. In this paper both enzymes are studied with respect to their substrate specificities to provide information on mechanism. The isomerase is shown to be highly specific with respect to the ionylidene ring system and substitution at C15, whereas sterically bulkier substituents at C9 and C11 are permitted. C5 and C13 demethyl retinoids are isomerized, removing from consideration isomerization mechanisms involving C-H abstraction at the C5 or C13 methyl groups of the retinoid. On the other hand, C9 demethyl retinoids are not isomerized. A C-H abstraction mechanism is unlikely at the C9 methyl group as well, because no kinetic deuterium isotope effect is found with *all-trans*-19,19,19-trideuterio retinoids and isomerization of unlabeled retinoids occurs without the incorporation of deuterium when the isomerization is performed in D<sub>2</sub>O. LRAT proved to be broadly specific for retinols but was relatively inert with other hydrophobic alcohols including cholesterol. The enzyme is also highly specific for phosphatidylcholine analogues versus other potential membranous acyl donors such as phosphatidylethanolamine and phosphatidylserine.

Vision begins with the photoisomerization of the 11-*cis*-retinal Schiff base chromophore of rhodopsin to its *all-trans*-retinal congener (Hubbard & Wald, 1952). *all-trans*-Retinal is reduced in the rod outer segments to *all-trans*-retinol (vitamin A) and carried off to the pigment epithelium where it is esterified and isomerized to produce 11-*cis*-retinol (Deigner et al., 1989). In warm-blooded mammals, at least, the 11-*cis*-retinol is oxidized to 11-*cis*-retinal in the pigment epithelium (Jones et al., 1989) and returned to the rod outer segments, where it recombines with opsin to form rhodopsin.

The retinoid isomerization process is an intriguing one because it involves the input of chemical energy to drive the thermodynamically uphill trans to cis isomerization reaction. 11-*Cis* retinoids are approximately 4 kcal/mol higher in energy

than their *all-trans* isomers (Rando & Chang, 1983). This problem is solved in the visual system by a mechanism that involves the initial esterification of vitamin A, catalyzed by a lecithin retinol acyltransferase (LRAT)<sup>1</sup> (Barry et al., 1989; Saari & Bredberg, 1989). This enzyme transfers a saturated acyl group from the *sn*-1 position of lecithin, thereby producing a retinyl ester and a 2-acyl lysophospholipid as products (Barry et al., 1989; MacDonald & Ong, 1988; Saari & Bredberg, 1989). In a separate reaction, the retinyl ester is isomerized with hydrolysis to produce 11-*cis*-retinol and a fatty acid (Deigner et al., 1989). In this isomerase- (or more properly isomerohydrolase-) mediated reaction, the required energy is provided by the free energy of hydrolysis of the retinyl ester (Deigner et al., 1989). Thus, retinyl ester synthesis is obligate

<sup>†</sup> This work was supported by U.S. Public Health Service Research Grants EY-04096 (R.R.R.) and GM-36564 (K.N.) from the National Institutes of Health. F.J.C. is a recipient of a CSIC (Spain) postdoctoral fellowship.

\* To whom correspondence should be addressed.

<sup>1</sup> Abbreviations: LRAT, lecithin retinol acyltransferase; RPE, retinal pigment epithelium; MS, mass spectroscopy; BSA, bovine serum albumin; BHT, butylated hydroxytoluene; THF, tetrahydrofuran; PC, phosphatidylcholine; PG, phosphatidylglycerol; PS, phosphatidylserine; PE, phosphatidylethanolamine; PA, phosphatidic acid.

in the isomerization pathway, a point explicitly demonstrated with specific inhibitors of LRAT (Trehan et al., 1990). Inhibitors of LRAT act pleiotropically by preventing the conversion of *all-trans*-retinol to *all-trans*-retinyl esters and preventing the formation of 11-*cis*-retinol (Trehan et al., 1990). The inhibitors do not prevent the processing of *all-trans*-retinyl esters into 11-*cis*-retinol (Trehan et al., 1990).

Since the retinyl esters are generated with phospholipids as the source of acyl groups, the energy to drive the isomerization reaction resides in the phospholipid membranes. Hence, the phospholipids are being used as ATP surrogates in group transfer reactions in the membrane (Deigner et al., 1989).

The specificities and mechanisms of action of the LRAT and isomerase enzymes remain unexplored. In this paper, the specificities of the two enzymes with respect to substrates are studied, and aspects of the isomerase mechanism are determined. LRAT is specific for phosphatidylcholine and regiospecific for the 1-position of this phospholipid. Only retinols and similar molecules are esterified by the enzyme. Substrate/activity profiles and mechanistic studies on the isomerase demonstrate that it is highly specific and that it is extremely unlikely that it functions through a carbanion mechanism.

## MATERIALS AND METHODS

### Materials

Frozen eye cups devoid of retinae were obtained from J. A. and W. L. Lawson Co., Lincoln, NE. [11,12-<sup>3</sup>H]-*all-trans*-Retinol (60 Ci/mmol) and [7(n)-<sup>3</sup>H]cholesterol (**19**) (7.8 Ci/mmol) were obtained from Du Pont-New England Nuclear, and sodium boro[<sup>3</sup>H]hydride (20 Ci/mmol, 1.25 mM in 0.1 M sodium hydroxide) was from Amersham; retinal, retinol (**1**), cinnamaldehyde, cinnamyl alcohol (**16**), citral, geraniol (**17**), tetradecanal, and tetradecanol (**18**), were from Fluka;  $\beta$ -ionone and deuterium oxide (99.9% deuterium) were from Aldrich, and 1,2-divaleroyl-*sn*-glycero-3-phosphocholine (divaleroyl-PC) was from Sigma. 1,2-Dioleoyl-*sn*-glycero-3-phosphocholine (dioleoyl-PC), 1,2-dioleoyl-*sn*-glycero-3-phosphoserine (dioleoyl-PS), 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (dioleoyl-PE), 1,2-dioleoyl-*sn*-glycero-3-phosphoglycerol (dioleoyl-PG), 1,2-dioleoyl-*sn*-glycero-3-phosphatidic acid (dioleoyl-PA), and 1-oleoyl-*sn*-glycero-3-phosphocholine (monooleoyl-PC) were from Avanti Polar Lipids. HPLC-grade solvents were from J. T. Baker.

### Methods

**Syntheses of Retinol Analogues.** The retinals were prepared according to the indicated published procedures. The *all-trans*, 11-*cis*, and 13-*cis* isomers of the retinol analogues, unless specified otherwise, were prepared under dim red light by NaBH<sub>4</sub> reduction of the corresponding HPLC-pure retinal isomers; each alcohol was then purified by HPLC and its configuration ascertained by PMR and UV spectroscopy.

*all-trans*-Retinyl methyl ether (**2**) was synthesized as described earlier (Hanze et al., 1948). *all-trans*-15-Methylretinol (**3**) was synthesized as described in the published synthesis of 15-methylretinone (Ebrey et al., 1975). *all-trans*-10,12-Ethyleneretinal (**4**) was prepared according to the published method (Fang et al., 1983). *all-trans*-Phenylretinal (**5**) and *all-trans*-(2,6-dimethylphenyl)retinal (**6**) were synthesized by the published method (Derguini et al., 1984). *all-trans*-5-Demethylretinal (**7**) was obtained according to Courtin et al. (1987). *all-trans*-13-Demethylretinol (**8**) was synthesized as described earlier (Gartner et al., 1980). *all-trans*-9-Demethylretinol (**9**) was a gift of W. Gartner. *all-trans*-9,11-Trimethyletherretinal (**10**) [or 3-methyl-5,7-trimethyle-

(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol] was a gift of M. Sheves. *all-trans*-19,19,19-Trifluororetinal (**11**) was prepared according to Hanzawa et al. (1985).

*all-trans*-19,19,19-Trideuterioetretinal (**12**) was synthesized from 9-(trideuteriomethyl)- $\beta$ -ionone [*trans*-1,1,1-trideuterio-4-(6,6,2-trimethylcyclohex-1-enyl)-3-buten-2-one], which was obtained by condensation of CD<sub>3</sub>MgI with *trans*-3-(6,6,2-trimethylcyclohex-1-enyl)-2-propen-1-al followed by MnO<sub>2</sub> oxidation. 9-(Trideuteriomethyl)- $\beta$ -ionone was then converted to *all-trans* and 9-*cis* C<sub>15</sub> aldehyde through condensation with the anion of (trimethylsilyl)acetaldehyde *tert*-butylimine. The *trans* C<sub>15</sub> aldehyde isomer was converted into the desired chromophore through a conventional Emmons reaction with the anion of ethyl phosphonosencioate (Pattenden & Weedon, 1968), Dibal reduction, MnO<sub>2</sub> oxidation, and HPLC separation of isomers.

*all-trans*-5-Methyl-7-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6-heptatrien-1-ol (C<sub>17</sub> alcohol) (**13**) and *all-trans*-3-methyl-5-(2,6,6-trimethyl-1-cyclohexenyl)-2,4-pentadien-1-ol (C<sub>15</sub> alcohol) (**14**) were intermediates in the synthesis of **8** (Gartner et al., 1980).

**Synthesis of Radioactive Analogues.** The 15-<sup>3</sup>H-labeled *all-trans*-retinol analogues (**3**–**12**) were prepared by reduction of an excess of the corresponding aldehydes, dissolving in 200  $\mu$ L of 2-propanol (distilled from NaBH<sub>4</sub>), with 100  $\mu$ L of sodium boro[<sup>3</sup>H]hydride solution. The labeled alcohols were extracted with hexane and purified by HPLC on a silica column (SiO<sub>2</sub>, 4  $\times$  250 mm Hibar, Merck). The eluting solvent was 7% dioxane in *n*-hexane at 2 mL/min [2.5 mL/min in the case of the aromatic analogues (**5** and **6**)] or hexane-ethyl acetate-2-propanol (90:10:1) at 1 mL/min with **4**. The peak corresponding to the *all-trans* alcohol was collected and stored in the presence of BHT at -20 °C until use. The recovery of radioactivity in the *all-trans* alcohols was from 10 to 25%. The label in the 15-position of *all-trans*-retinol was not lost during its isomerization (Bernstein et al., 1987b). The other <sup>3</sup>H-labeled hydrophobic alcohols (**13**–**18**) and [15-<sup>3</sup>H]-11-*cis*-retinol (**20**) were prepared and purified in a similar way.

[11,12-<sup>3</sup>H]-*all-trans*-Retinyl methyl ether (**2**) was prepared as published (Hanze et al., 1948) but with radioactive retinol as starting material. [11,12-<sup>3</sup>H]-*all-trans*-15-Methylretinol (**3**) (5 Ci/mmol) was obtained by reaction of methylolithium with [<sup>3</sup>H]-*all-trans*-retinal at 0 °C in ether.

**Preparation of Standard Isomeric Mixtures.** The mixtures of each analogue were prepared by mixing the reduced isomerically pure aldehydes previously identified by HPLC. The mixture of palmitate esters was made in a similar way by acylating isomerically pure alcohols with palmitoyl chloride and pyridine in dry THF (Isler et al., 1949). Valerate esters of **1**, **13**, and **14** were prepared by the same procedure.

**Enzymatic Assays.** Bovine pigment epithelium membranes were prepared as described elsewhere (Barry et al., 1989) and irradiated with UV light to deplete endogenous retinols (Deigner et al., 1989). A stock suspension (1.1  $\mu$ M) of each of the *all-trans* alcohols was prepared as follows: 5  $\mu$ Ci of the *all-trans* alcohol (5 Ci/mmol) in hexane was dried with a gentle N<sub>2</sub> stream. BSA (fat free), 100  $\mu$ L (5% in phosphate buffer, 50 mM, pH 7.4), was added to the dried residue. The mixture was vortexed and then diluted with 800  $\mu$ L of phosphate buffer. An aliquot (180  $\mu$ L) of this suspension was mixed with 20  $\mu$ L of pigment epithelium membranes (10 mg/mL). Final concentrations in the standard experiments were 1 mg/mL protein, 1  $\mu$ M labeled substrate, and 0.5% (w/v) BSA. The mixture was incubated for 1 or 2 h at 37

°C with shaking. Control experiments were performed with buffer or boiled membranes instead of enzymatically active membranes.

Partially purified enzyme was used where indicated. In this case, the LRAT activity was solubilized and purified as previously described (Barry et al., 1989). Stock solutions of the radioactive alcohols were prepared in the same way as before. The incubations were performed with 0.07 mg of protein/mL, 1  $\mu$ M labeled substrate, 1 mM divaleryl-PC, and 0.5% BSA. Times of incubation were up to 1 h at 37 °C.

When different lipids were used, a stock suspension (3.2 mM) of each lipid was prepared by sonication of the lipid in phosphate buffer. Final lipid concentrations in the assay were 0, 0.2, 0.4, or 0.8 mM along with 0.06 mg of protein per milliliter of partially purified enzyme, 0.5  $\mu$ M [15-<sup>3</sup>H]-*all-trans*-retinol, and 0.5% BSA. The mixtures were incubated for 1 h at 37 °C.

The incubations were quenched by the addition of 500  $\mu$ L of a cold mixture of methylene dichloride-methanol (1:1). After vortexing, 100  $\mu$ L of brine was added and the mixture vortexed again. The phases were separated by centrifugation. The lower phase was removed and dried with N<sub>2</sub>. The upper layer was reextracted with 500  $\mu$ L of hexane. The hexane layer was added to the dried extract. The extent of extraction was higher than 95% as determined by measuring the radioactivity remaining in the complete aqueous phase and in an aliquot of the hexane phase.

**Enzymatic Reactions Carried Out in D<sub>2</sub>O.** RPE membranes were prepared as described but with D<sub>2</sub>O instead of water in all buffers. The buffer components were allowed to exchange with D<sub>2</sub>O followed by evaporation of the deuterated water. This cycle was repeated several times to remove the exchangeable H. A mixture of *all-trans*-retinol (2  $\mu$ M) and RPE membranes (1 mg of protein/mL) in 15 mL of deuterated buffer with 0.5% BSA was incubated for 2 h at 37 °C. Cold methanol (10 mL) was added, and the retinoids were extracted twice with hexane (10 mL). The retinoids were purified by HPLC. 11-*cis*- and 13-*cis*-Retinoids were separated from *all-trans*-retinol and the endogenous cholesterol with 10% diethyl ether in hexane as the eluant. A second purification with 7% dioxane in hexane separated 11-*cis*- from 13-*cis*-retinol and *all-trans*-retinol from cholesterol. Each isomer was analyzed separately by field desorption MS as described (Deigner et al., 1989). The ratio  $M + 1/M_{286}$  was calculated from the mass spectra. An experiment to control for the possible occurrence of nonspecific exchange was carried out on a heat-denatured membrane preparation in D<sub>2</sub>O with 11-*cis*-retinol instead of *all-trans*-retinol.

**Kinetic Studies.** [15-<sup>3</sup>H]-*all-trans*-Retinol (**1**) and [15-<sup>3</sup>H]-*all-trans*-19,19,19-trideuterio-retinol (**12**) were prepared with the same sodium boro[<sup>3</sup>H]hydride. Assays with RPE membranes (0.5 mg/mL) and concentrations of **1** between 0.2 and 4  $\mu$ M (actual concentrations of substrates were calculated by measuring the radioactivity in an aliquot of the incubation mixtures) were conducted for up to 30 min at 37 °C. Identical experiments were performed with **12**. Under the assay conditions, the isomerization was linear with respect to protein concentration.

**HPLC Analyses.** A 150- $\mu$ L aliquot of the hexane phase, to which a standard mixture of isomeric alcohols was added for UV detection, was analyzed by HPLC under the conditions described for the purification of the <sup>3</sup>H-labeled *all-trans* alcohols. The percentage of isomerization and esterification was measured as the percentages of radioactivity associated with the 11-*cis* alcohol and esters peaks, respectively, in the chro-

Table I: Substrate Specificity for the Isomerase

analogue <sup>a</sup>	11- <i>cis</i> alcohol <sup>b</sup>	retinyl ester <sup>c</sup>	11- <i>cis</i> esters <sup>d</sup>	total 11- <i>cis</i> retinoids <sup>e</sup>
<b>1</b> (+enzyme)	12.8 $\pm$ 3.3	71.0 $\pm$ 3.9	15.8 $\pm$ 3.5	24.0 $\pm$ 3.0
<b>1</b> (-enzyme)	0.5 $\pm$ 0.1			0.5 $\pm$ 0.1
<b>2</b> (+enzyme)	0.2 $\pm$ 0.1			0.2 $\pm$ 0.1
<b>2</b> (-enzyme)	0.1 $\pm$ 0.1			0.1 $\pm$ 0.1
<b>3</b> (+enzyme)	0.6 $\pm$ 0.2	39.1 $\pm$ 24	0.4 $\pm$ 0.3	0.8 $\pm$ 0.4
<b>3</b> (-enzyme)	1.0 $\pm$ 0.2			1.0 $\pm$ 0.2
<b>4</b> (+enzyme)	0.2 $\pm$ 0.1	60.1 $\pm$ 5.0	2.5 $\pm$ 1.6	1.8 $\pm$ 1.2
<b>4</b> (-enzyme)	0.7 $\pm$ 0.1			0.7 $\pm$ 0.1
<b>5</b> (+enzyme)	0.8 $\pm$ 0.1	82.4 $\pm$ 3.1	$\leq 2$	1.9 $\pm$ 0.5
<b>5</b> (-enzyme)	5.7 $\pm$ 1.0			5.7 $\pm$ 1.0
<b>6</b> (+enzyme)	0.2 $\pm$ 0.2	91.7 $\pm$ 1.1	1.6 $\pm$ 0.6	1.9 $\pm$ 0.7
<b>6</b> (-enzyme)	0.3 $\pm$ 0.1			0.3 $\pm$ 0.1
<b>7</b> (+enzyme)	6.2 $\pm$ 0.5	74.9 $\pm$ 2.4	6.4 $\pm$ 1.0	11.0 $\pm$ 0.5
<b>7</b> (-enzyme)	0.7 $\pm$ 0.3			0.7 $\pm$ 0.3
<b>8</b> (+enzyme)	6.2 $\pm$ 0.6	75.0 $\pm$ 1.3	1.3 $\pm$ 0.1	7.2 $\pm$ 0.5
<b>8</b> (-enzyme)	1.2 $\pm$ 0.2			1.2 $\pm$ 0.2
<b>9</b> (+enzyme)	0.3 $\pm$ 0.1	88.6 $\pm$ 9.9	0.8 $\pm$ 0.1	1.0 $\pm$ 0.3
<b>9</b> (-enzyme)	0.9 $\pm$ 0.1			0.9 $\pm$ 0.1
<b>10</b> (+enzyme)	1.7 $\pm$ 0.2	94.1 $\pm$ 0.4	42.9 $\pm$ 7.9	42.1 $\pm$ 8.0
<b>10</b> (-enzyme)	2.8 $\pm$ 1.5			2.8 $\pm$ 1.5
<b>11</b> (+enzyme)	0.5 $\pm$ 0.1	70.3 $\pm$ 1.1	$\leq 1$	0.7 $\pm$ 0.1
<b>11</b> (-enzyme)	1.0 $\pm$ 0.2			1.0 $\pm$ 0.2

<sup>a</sup> Each analogue was incubated for 2 h with pigment epithelium membranes (+enzyme) or with buffer only (-enzyme) as described under Methods except for compounds **2** and **3**, which were incubated with frog retinal pigment epithelium membranes under the same conditions as published (Law et al., 1988). <sup>b</sup> Percentage of 11-*cis* alcohol in the total pool of retinoids. <sup>c</sup> Percentage of esterified compounds in the total pool of retinoids. <sup>d</sup> Percentage of 11-*cis* isomers in the ester pool. <sup>e</sup> Percentage of 11-*cis* retinoids as alcohols and esters in the total pool of retinoids. <sup>f</sup> The incubation time was 1 h at 37 °C.

matogram (Bernstein et al., 1987a). The radioactivity was measured with a Berthold radioactivity detector on line with the HPLC system.

The analysis of the 11-*cis* retinoids in the ester pools was performed in a similar way. To an aliquot of the reaction mixture, the corresponding mixture of nonradioactive isomeric esters was added, and analysis was performed by HPLC (SiO<sub>2</sub>, two columns in series, 0.7% ether in hexane, 1 or 1.5 mL/min for aromatic analogues). The palmitate esters of the 11-*cis* isomers of **3**, **5**, **10**, and **11** were not completely resolved from the other isomers. To resolve the isomers, an aliquot of the reaction mixture was hydrolyzed with 5% KOH in methanol (5 min at 0 °C), and the resulting retinoids were analyzed as described (Bernstein et al., 1987a).


## RESULTS

### Specificity of the Isomerase

We had previously shown that the isomerization reaction is stereospecific with respect to the double-bond configuration of the retinyl esters (Law et al., 1988). The isomerase only interconverts *all-trans* and 11-*cis* retinoids. Here we are interested in a broader study of the structure/activity requirements for the isomerase. It is anticipated that these studies will be important in defining the mechanism of action of this novel enzyme system. It should be noted that, in all of the cases described below where activity was observed, the retinols were first converted into their corresponding retinyl esters before isomerization occurred. The retinol analogues studied are shown in Chart I.

**Modifications at the 15-Position of *all-trans*-Retinol.** Two relatively simple molecules were initially studied (Table I). Neither *all-trans*-retinyl methyl ether (**2**) nor 15-methylretinol (**3**) was appreciably isomerized. The latter compound was esterified to its retinyl ester congener but resisted isomerization.

Chart I: Retinol Analogues



Since the former compound could not be esterified, it could not be processed into an 11-*cis*-retinol. An additional compound was studied which contained a five-membered ring adjacent to the 15-position (4). This molecule was again esterified but not isomerized.

**Aromatic Analogues of all-trans-Retinol.** Both the phenyl (5) and 2,6-dimethylphenyl analogues (6) of *all-trans*-retinol were studied (Table I). Both analogues were esterified by the endogenous LRAT activity, but neither ester was further processed to its corresponding 11-*cis*-retinol.

**Modifications at the Methyl Groups of all-trans-Retinol.** As one important mechanistic possibility for the isomerase involves a C-H bond abstraction followed by C-O bond cleavage, it was important to investigate the demethylretinol series (Table I). Both 5-demethylretinol (7) and 13-demethylretinol (8) were esterified by endogenous LRAT and further isomerized to provide the corresponding 11-*cis*-retinols. Interestingly, the corresponding experiment with *all-trans*-9-demethylretinol (9) showed esterification but no isomerization. The molecular bulk requirement at the C9 position was further studied with retinoid (10). This molecule was readily esterified and isomerized. In fact, it appeared to be a better substrate than *all-trans*-retinol itself. Thus, the C9 position appears not to be sensitive to steric interactions as long as there is an alkyl group present.

The possibility that C-H abstraction at the C9 methyl group of *all-trans*-retinol is important in the isomerization reaction was further considered. 19,19,19-Trifluororetinol (11), a molecule in which C-H abstraction is impossible, was prepared and studied (Table I). Again, esterification occurred but not isomerization. However, the strong electron-withdrawing character of the trifluoromethyl group must also be considered as a possible reason why a negative result was obtained in the isomerization reaction.

**Isotope Effect and Solvent-Incorporation Studies.** To further address the issue of whether C-H abstraction occurs during the isomerization reaction, the kinetic behavior of *all-trans*-19,19,19-trideuterio-retinol (11) was studied in the isomerase reaction. Observation of a primary deuterium isotope effect would signal the occurrence of a rate-limiting C-H abstraction mechanism. We found 11 to behave almost





FIGURE 1: Rate of isomerization of *all-trans*-retinol (1) and *all-trans*-19,19,19-trideuterio-retinol (12). Michaelis-Menten plot (upper panel) and Lineweaver-Burk plot (lower panel) of 11-*cis*-retinol production as function of *all-trans*-retinol concentration. Incubations were carried out as described under Methods. (O, —) *all-trans*-Retinol (1) ( $V_{\max} = 411 \pm 18$  pmol mg<sup>-1</sup> h<sup>-1</sup>;  $K_m = 0.57 \pm 0.5$  μM); (●, ---) *all-trans*-19,19,19-trideuterio-retinol (12) ( $V_{\max} = 393 \pm 12$  pmol mg<sup>-1</sup> h<sup>-1</sup>;  $K_m = 0.53 \pm 0.4$  μM).

identically with *all-trans*-retinol in its ability to be both esterified and isomerized to its 11-*cis*-retinol congener. As shown in Figure 1, the  $V_{\max}$ 's for the deuterated and nondeuterated compounds were the same [approximately 0.4 nmol (mg of protein)<sup>-1</sup> h<sup>-1</sup>] within experimental error. Furthermore, the two retinols also showed virtually identical apparent  $K_m$ 's. Therefore, rate-limiting C-H abstraction at the 9-methyl does not occur during isomerization.

The antipode of the experiment with 11 is to carry out the isomerase experiment with *all-trans*-retinol in D<sub>2</sub>O. Even if



Scheme I: Possible Isomerohydrolase Mechanisms



& Ong, 1988; Saari & Bredberg, 1989).

## DISCUSSION

The biosynthesis of 11-*cis*-retinol in the pigment epithelium of vertebrates requires two enzymatic activities (Deigner et al., 1989). First, the *all-trans*-retinol, delivered from the photoreceptors, must be esterified to produce *all-trans*-retinyl esters (Deigner et al., 1989). The *trans*-retinyl esters, chiefly of the palmitate series, are then processed directly to 11-*cis*-retinol by an isomerohydrolase enzyme (Deigner et al., 1989). Following retinol dehydrogenase mediated oxidation of 11-*cis*-retinol to 11-*cis*-retinal, the latter is transported back to the photoreceptors (at least in mammals), where it can combine with opsin to regenerate rhodopsin (Jones et al., 1989). That *all-trans*-retinyl esters are the direct precursors of 11-*cis*-retinol was unambiguously demonstrated by showing that inhibitors of LRAT, such as *all-trans*-retinyl  $\alpha$ -bromoacetate, prevent the biosynthesis of 11-*cis*-retinol from *all-trans*-retinol (Trehan et al., 1990). The requirement of a retinyl ester precursor to 11-*cis*-retinol is understood in energetic terms (Deigner et al., 1989). In this type of reaction, the free energy of hydrolysis of the retinyl esters is coupled to the endothermic isomerization, providing the necessary free energy to drive the latter process (Deigner et al., 1989).

Several distinct mechanisms can be considered for the isomerase reaction (Scheme I). Scheme IA shows an S<sub>N</sub>2' mechanism, Scheme IB shows C-H abstraction mechanisms, and Scheme IC shows a carbonium ion mechanism. From previous structure/activity studies it is clear that none of the dihydro analogues of *all-trans*-retinol are isomerized, although all of them are esterified by LRAT (Law et al., 1988). These observations suggest substantial substrate specificity for the

isomerase, but they are not informative as to mechanism. Some of the most interesting retinoid analogues studied here focused on the role of the appended alkyl groups of *all-trans*-retinol. Both the 5- and 13-demethylretinyl esters were isomerized. These observations rule out possible C-H abstraction at either of these sites in the isomerization reaction. Previous studies (Law et al., 1988) showed that *all-trans*-3,4-didehydroretinol (vitamin A<sub>2</sub>) was isomerized, also ruling out possible C-H abstraction from the ionylidene ring as being mechanistically important. The fact that *all-trans*-9-demethylretinyl ester was not isomerized points to a possible important role for the 9-methyl group in the isomerization process. However, this role is unlikely to involve C-H abstraction because the  $V_{\max}$ 's and apparent  $K_M$ 's for the isomerizations of *all-trans*-19,19,19-trideuterioretinol and *all-trans*-retinol were essentially identical. The  $V_{\max}$ 's for *all-trans*-19,19,19-trideuterioretinol and *all-trans*-retinol were both approximately 0.4 nmol mg<sup>-1</sup> h<sup>-1</sup>. It should be noted that the absolute value for the  $V_{\max}$  underestimates the true  $V_{\max}$  of the isomerizing system because the amount of 11-*cis*-retinyl esters formed is not considered and the 11-*cis*-retinol that is formed is unstable and can nonenzymatically isomerize back to its *all-trans* congener (Deigner et al., 1989). The actual maximal rate of overall isomerization capability in the bovine pigment epithelium membranes is closer to 1–2 nmol mg<sup>-1</sup> h<sup>-1</sup> after corrections for the formation of 11-*cis*-retinyl esters and the thermal instability of 11-*cis*-retinol are made.

In addition to the lack of an observable kinetic isotope effect, deuterium incorporation into 11-*cis*-retinol was not observed when the isomerization reaction was performed in D<sub>2</sub>O. The observed lack of deuterium incorporation is also inconsistent with a C-H abstraction mechanism unless the proton ab-

stracted was also added back. This could occur in the absence of H<sub>2</sub>O, but this is considered unlikely here because water is required to hydrate the isomerization intermediate (Scheme I).

Other substituted analogues at the 9-position were also investigated. Analogue **10** was readily processed into its 11-*cis*-retinol analogue, demonstrating that sterically bulkier groups than the methyl group are allowed at the C9 position. This analogue is also interesting since its 11-*cis* congener is relatively stable compared to the all-*trans* form because of the trimethylene moiety adducted to the C11 position. In this configuration, steric interaction between this methylene moiety and the 13-methyl group renders the *trans* configuration unstable. This interaction is relieved in the 11-*cis* configuration. The fact that this analogue is active also shows that substitution at the 11-position is permitted. Given these observations, the fact that all-*trans*-19,19-trifluororetinol is inactive can probably be understood in electronic terms. On the basis of these studies in aggregate, it is highly unlikely that a C-H abstraction mechanism (Scheme IB) is important in the isomerase-mediated reaction.

It is interesting to compare some of these results with those obtained on analogue studies with rhodopsin. Both 11-*cis*-5- and 13-demethylretinals form biochemically competent rhodopsins (Blatz et al., 1988; Kropf, 1976). 11-*cis*-9-Demethylretinal also forms a photoisomerizable pigment with opsin (Eyring et al., 1980). However, unlike the other demethyl analogues, the pigment formed from 11-*cis*-9-demethylretinal fails to produce the biochemically active form of rhodopsin (metarhodopsin 2) upon photoisomerization (Ganter et al., 1989). It is possible that the 9-methyl group is pivotal in pushing against both the isomerases and opsin proteins concomitant with isomerization. This interaction could then lead to the key conformational changes of the proteins required to produce a fruitful biochemical event.

Consideration of the structure/activity relationships for isomerization reveals fairly strict structural requirements. The ionylidene ring system cannot be substituted for by phenyl groups (**5** and **6**), and sterically bulky groups at the C15 terminus of the retinoid are not tolerated (**3** and **4**). As expected, O-methylation of all-*trans*-retinol leads to an inert compound. Only at the center of the molecule, i.e., positions 9 and 11, is bulkier substitution allowable. As mentioned before, a substituent at the C9 position is critical for activity.

In addition to determining the specificity of an enzyme, structure/activity studies can also be important in gaining insights into enzyme mechanism. The structure/activity studies performed so far, along with the deuterium incorporation and isotope studies, are inconsistent with a C-H abstraction mechanism, and one can probably rule this mechanism out from further consideration. The studies reported here do not differentiate between the S<sub>N</sub>2' and carbonium ion mechanisms described in panels A and C of Scheme I, respectively. The marked effect of the trifluoromethyl substitution (**11**) could suggest the possible development of carbonium ion character during isomerization. However, more complete studies with variously fluorinated retinoids will be important before further conclusions can be drawn.

All of the all-*trans*-retinol analogues studied here (except for the methyl ether) and the dihydroretinols as previously studied (Law et al., 1988) were esterified by LRAT. These observations demonstrate a relatively nonspecific enzymatic activity within the retinol series. However, LRAT is relatively specific for the retinols when compared to other hydrophobic alcohols. Truncated versions of retinols (**13** and **14**) are weak

substrates, and hydrophobic alcohols structurally dissimilar to the retinols, such as cholesterol, were not esterified. As expected, 11-*cis*-retinol was also esterified, although less efficiently than all-*trans*-retinol.

The specificity of LRAT with respect to lipid donors was also studied. It is clear that, of the major lipid classes, only phosphatidylcholine analogues are substantially processed. As previously noted, acyl transfer occurs in a regiospecific manner from the *sn*-1 position of phosphatidylcholine (Barry et al., 1989; MacDonald & Ong, 1988; Saari & Bredberg, 1989). We have found little specificity with respect to the fatty acyl groups. Divaleroyl-PC is a competent acyl donor (Barry et al., 1989). However, other studies have suggested that there may be some specificity directed toward naturally occurring phospholipids with regard to the nature of the unsaturated fatty acyl group at the *sn*-2 position (Saari & Bredberg, 1989).

Since LRAT has not yet been purified to homogeneity, it is not clear if isoenzymes exist whose activities can be separately regulated. This would be especially interesting with respect to the processing of all-*trans*-retinol and 11-*cis*-retinol. all-*trans*-Retinol serves no direct metabolic function and must be esterified to produce the isomerase substrate. 11-*cis*-Retinol, on the other hand, serves as the immediate precursor for the visual chromophore 11-*cis*-retinal. The esterification of 11-*cis*-retinol serves no obvious metabolic purpose other than to provide a storage mechanism. It is interesting that steady-state levels of 11-*cis*-retinol are much higher than those of all-*trans*-retinol in the dark (Hubbard & Dowling, 1962).

#### ACKNOWLEDGMENTS

all-*trans*-19,19-Trifluororetinol and all-*trans*-9-demethylretinol were generous gifts of Dr. Y. Kobayashi of the Tokyo College of Pharmacy and Dr. W. Gartner of the University of Freiburg. The cyclic all-*trans*-retinol (**10**) was a generous gift of Dr. M. Sheves of the Weizmann Institute of Science. Dr. Achla Trehan synthesized all-*trans*-13-demethylretinol and compounds **13** and **14**. We are indebted to Dr. T. Higuchi of JEOL Inc. for the mass spectroscopic measurements. The excellent technical assistance of M. Sarma is gratefully acknowledged.

#### REFERENCES

- Barry, R. J., Cañada, F. J., & Rando, R. R. (1989) *J. Biol. Chem.* **264**, 9231-9238.
- Bernstein, P. S., Law, W. C., & Rando, R. R. (1987a) *Proc. Natl. Acad. Sci. U.S.A.* **84**, 1849-1853.
- Bernstein, P. S., Law, W. C., & Rando, R. R. (1987b) *J. Biol. Chem.* **262**, 16848-16857.
- Blatz, P. E., Lin, M., Balasubramanian, P., Balasubramanian, V., & Dewhurst, P. B. (1988) *J. Am. Chem. Soc.* **91**, 5903-5931.
- Courtin, J. M. L., Verhagen, L., Biesheuvel, P. L., & Lugtenburg, J. (1987) *Recl. Trav. Chim. Pays-Bas* **106**, 112-119.
- Deigner, P. S., Law, W. C., Cañada, F. J., & Rando, R. R. (1989) *Science* **244**, 968-971.
- Derguini, F., Bigge, C. F., Croteau, A. A., Balogh, V., & Nakanishi, K. (1984) *Photochem. Photobiol.* **39**, 661-665.
- Ebrey, T., Govindjee, B., Honig, B., Pollok, E., Chan, W., Crouch, R., Yudd, Y., & Nakanishi, K. (1975) *Biochemistry* **14**, 3933-3941.
- Eyring, G., Curry, B., Mathies, R., Fransen, R., Palings, I., & Lugtenburg, J. (1980) *Biochemistry* **19**, 2410-2418.
- Feng, J.-M., Carriker, J. D., Balogh-Nair, V., & Nakanishi, K. (1983) *J. Am. Chem. Soc.* **105**, 5162-5164.

- Ganter, U. M., Schmid, E. D., Perez-Sala, D., Rando, R. R., & Siebert, F. (1989) *Biochemistry* 28, 5954-5962.
- Gartner, W., Hopf, H., Hull, W. H., Oesterhelt, D., Scheutzw, D., & Towner, T. (1980) *Tetrahedron Lett.* 21, 347-350.
- Hanzawa, Y., Yamada, A., & Kobayashi, Y. (1985) *Tetrahedron Lett.* 26, 2881-2884.
- Hanze, A. R., Conger, T. W., Wise, E. C., & Weisblat, D. I. (1948) *J. Am. Chem. Soc.* 70, 1253-1256.
- Hubbard, R., & Wald, G. (1952) *J. Gen. Physiol.* 36, 269-315.
- Hubbard, R., & Dowling, J. E. (1962) *Nature* 193, 341-343.
- Isler, O., Ronco, A., Guex, W., Hindley, N. C., Huber, W., Dialer, K., & Kofler, M. (1949) *Helv. Chim. Acta* 32, 489-505.
- Jones, G. J., Crouch, R. K., Wiggert, B., Cornwall, M. C., & Chader, G. J. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86, 9606-9610.
- Kropf, A. (1976) *Nature* 264, 92-94.
- Law, W. C., Rando, R. R., Canonica, S., Derguini, F., & Nakanishi, K. (1988) *J. Am. Chem. Soc.* 110, 5915-5917.
- MacDonald, P. N., & Ong, D. E. (1988) *Biochem. Biophys. Res. Commun.* 156, 157-163.
- Pattenden, G., & Weedon, B. C. L. (1968) *J. Chem. Soc., C*, 1984-1997.
- Rando, R. R., & Chang, A. (1983) *J. Am. Chem. Soc.* 105, 2879-2882.
- Saari, J. C., & Bredberg, D. L. (1989) *J. Biol. Chem.* 264, 8636-8640.
- Trehan, A., Cañada, F. J., & Rando, R. R. (1990) *Biochemistry* 29, 309-312.

## Fusion of Influenza Hemagglutinin-Expressing Fibroblasts with Glycophorin-Bearing Liposomes: Role of Hemagglutinin Surface Density<sup>†</sup>

Harma Ellens,<sup>\*,§</sup> Joe Bentz,<sup>‡</sup> Diane Mason,<sup>§</sup> Fen Zhang,<sup>⊥</sup> and Judith M. White<sup>§</sup>

Department of Pharmacology and the Cell Biology Program, University of California, San Francisco, California 94143-0450, Department of Bioscience and Biotechnology, Drexel University, Philadelphia, Pennsylvania 19104, Department of Anatomy and Cell Biology, University of North Carolina, Chapel Hill, North Carolina 27514, and Department of Drug Delivery, Smith, Kline Beecham Pharmaceuticals, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939

Received January 16, 1990; Revised Manuscript Received July 9, 1990

**ABSTRACT:** Influenza virus gains access to the cytoplasm of its host cell by means of a fusion event between viral and host cell membrane. Fusion is mediated by the envelope glycoprotein hemagglutinin (HA) and is triggered by low pH. To learn how many hemagglutinin trimers are necessary to cause membrane fusion, we have used two NIH 3T3 fibroblast cell lines that express HA protein at different surface densities. On the basis of quantitations of the number of HA trimers per cell and the relative surface areas of the two cell lines, the HAb-2 cells have a 1.9-fold higher plasma membrane surface density than the GP4F cells. The membrane lateral diffusion coefficient and the mobile fraction for HA is the same for both cell lines. A Scatchard analysis of the binding of glycophorin-bearing liposomes to the cells showed 1700 binding sites for the GP4F cells and 3750 binding sites for the HAb-2 cells, with effectively the same liposome-cell binding constant, about  $7 \times 10^{10} \text{ M}^{-1}$ . Binding was specific for glycophorin on the liposomes and HA expressed on the cells. A competition experiment employing toxin-containing and empty liposomes allowed us to quantitate the number of liposomes that fused per cell, which was a small constant fraction of the number of bound liposomes. For the HAb-2 cells, about 1 in every 70 bound liposomes fused and for the GP4F cells about 1 in every 300 bound liposomes fused. Hence, the HAb-2 cells showed 4.4 times more fusion per bound liposome, even though the surface density of HA was only 1.9 times greater. We conclude the following: (i) One HA trimer is not sufficient to induce fusion. (ii) The HA bound to glycophorin is not the HA that induces fusion. That is, even though each HA has a binding and a fusion function, those functions are not performed by the same HA trimer.

**H**emagglutinin, the major envelope glycoprotein of influenza virus, is responsible for binding the virus to sialic acid containing receptors on the host cell surface (Hirst, 1941) and for initiating the fusion event between viral and cellular

membranes [e.g., Maeda and Ohnishi (1980), Matlin et al. (1981), and White et al. (1982)]. The ectodomain of HA<sup>1</sup> has been crystallized (Wilson et al., 1981) and shown to undergo a conformational change at the pH associated with viral fusion (Skehel et al., 1982; Doms et al., 1985; Ruigrok et al.,

<sup>†</sup>Supported in part by research grants from the American Cancer Society (H.E.), the National Institutes of Health GM31506 (J.B.), and AI22470 (J.M.W.), and the Pew Scholars Program in the Biomedical Sciences (J.M.W.).

\* Address correspondence to this author at Smith, Kline Beecham Pharmaceuticals.

<sup>‡</sup>Drexel University.

<sup>§</sup>University of California.

<sup>⊥</sup>University of North Carolina.

<sup>1</sup> Abbreviations: HA, hemagglutinin; HAO, the fusion-incompetent hemagglutinin precursor; HEPES, *N*-(2-hydroxyethyl)piperazine-*N'*-2-ethanesulfonic acid; PBS CMF, Ca<sup>2+</sup>- and Mg<sup>2+</sup>-free phosphate-buffered saline; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PMSF, phenylmethanesulfonyl fluoride; RBC, red blood cell; RIA, radioimmunoassay; TPCK, L-1-(tosylamino)-2-phenylethyl chloromethyl ketone; Tris, tris(hydroxymethyl)aminomethane.